| Wissenschaftl. Titel | An open label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PDL1. |
| Erkrankung |
Kopf-Hals:
Plattenepithelkarzinom:
Erstlinie
|
| Molekularer Marker |
HPV+ PD-L1 > 1% |
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (B) Weiterführende Informationen (F) Weiterführende Informationen (NIH) Weiterführende Informationen (EudraCT) |
erstellt 18.07.2022 Data entry III CCP
geändert 13.09.2023 Data entry II CCP